AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00970203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: androgen ablation (AA)
Description: Lupron 22.5 mg or Zoladex 10.8 mg
Study NCT00970203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC1 vaccine
Description: 3-5 x 10e6 cells total
Study NCT01686984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered breath
Study NCT01790061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized FMT
Description: Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
Study NCT01790061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional treatments
Description: Medications
Study NCT00564629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen plus oral placebo
Description: Single dose of 1 gm IV acetaminophen
Study NCT00564629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen plus IV placebo
Description: Single dose of 1 g PO APAP
Study NCT00564629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reference standard endotoxin (RSE)
Description: To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
Study NCT00564629 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference standard endotoxin (RSE)
Description: To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
Study NCT01347567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions with heart failure medications
Description: Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
Study NCT01347567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interventions with heart failure medications
Description: Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
Study NCT01347567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventions with heart failure medications
Description: Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
Study NCT02243124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
Study NCT02243124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
Study NCT03311178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
Study NCT02696512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypharmacy using FDA-approved products
Description: Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
Study NCT02696512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulation (MNS)
Description: 40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
Study NCT02696512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical Supplementation
Description: Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
Study NCT02696512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care treatment
Study NCT02696512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care treatment
Study NCT01373177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bayley Scales of Infant Development-II
Description: Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
Study NCT01373177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bayley Scales of Infant Development-III
Description: Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
Study NCT03488810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
Study NCT03488810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
Study NCT03488810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
Study NCT03488810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
Description: 2 injections of a three-monthly LHRH agonist depot
Study NCT03488810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
Description: 2 injections of a three-monthly LHRH agonist depot
Study NCT03488810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal anti-androgen
Description: Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
Study NCT04247932 — intervention group
Intervention type: BEHAVIORAL
Intervention: Active labor market intervention
Description: Behavior change intervention
Study NCT03246269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Study NCT01453192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
Study NCT04281927 — intervention group
Intervention type: DEVICE
Intervention: Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)
Description: Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
Study NCT01759134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post discharge formula
Description: Babies will be given either materna sensitive or similac neosure
Study NCT04534465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (MiraLAX, BAY81-8430)
Description: Oral solution, 17g polyethylene glycol, one time
Study NCT04534465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
Study NCT03727711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPTNS
Description: We will be comparing hospital treatment to TPTNS at home
Study NCT03727711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TPTNS
Description: We will be comparing hospital treatment to TPTNS at home
Study NCT00751881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet~Oral administration
Study NCT00751881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT00751881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT03067558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Children's automated respiratory rate monitor
Description: The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities.
Study NCT03067558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MK2 Acute Respiratory Infection (ARI) Timer
Description: The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
Study NCT02561377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
Study NCT02561377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
Study NCT03850288 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological assessment : Stroop task
Description: Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive.
Study NCT03850288 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological assessment : Go No Go task
Description: Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive.
Study NCT02579928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
Study NCT02579928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
Study NCT01979146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Unrelieved Symptom Alert
Description: The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
Study NCT05391594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customized posture support
Description: We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
Study NCT02689817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch
Description: A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
Study NCT04560725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Choline
Description: 11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
Study NCT03713866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EP Imaging and Testing
Description: Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation.
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT
Study NCT02702895 — intervention group
Intervention type: BEHAVIORAL
Intervention: In-depth Interview (IDIs) or Focus Group Discussion (FGD)
Study NCT03613038 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phonetic complexity effects on speech motor performance
Description: Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
Study NCT01800838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silicon phthalocyanine 4
Description: Given topically
Study NCT01800838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo PDT
Study NCT01800838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01800838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01370122 — intervention group
Intervention type: OTHER
Intervention: Survey
Study NCT01458886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 MD
Description: 2 puffs b.i.d. via Respimat inhaler
Study NCT01458886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler
Study NCT01458886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler
Study NCT01458886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: 2 puffs LD b.i.d. via Respimat inhaler
Study NCT01376882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
Study NCT01376882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and Placebo
Description: 100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
Study NCT01376882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and Caffeine
Description: Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
Study NCT01808703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PeriZone PerioPatch
Description: The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
Study NCT01808703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing alone
Description: Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
Study NCT01808703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing alone
Description: Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
Study NCT04156646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
Study NCT04156646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
Study NCT01373905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recruitment maneuver
Description: group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
Study NCT01373905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recruitment maneuver
Description: recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
Study NCT04258553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
Study NCT04258553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
Study NCT04258553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia Modified Albumin(IU/mL)
Description: The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
Study NCT03875573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
Study NCT03875573 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.
Study NCT03875573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
Study NCT04561427 — intervention group
Intervention type: OTHER
Intervention: Study of Sleep architecture in children with narcolepsy
Description: Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children